Our corporate member Asia-Euro Consultancy acted as advisor in a recently concluded Series C investment agreement CR-CP Life Science Fund in ReViral Ltd. Asia-Euro Consultancy was elemental in providing guidance to the joint sponsors in the fund, China Resources Group (the CR part in the fund name) and Charoen Pokphand Group (CP).
The Fund invests in leading life science companies that develop innovative drugs, cell therapies, medical devices and smart healthcare technologies.
Well done to the team at Asia-Euro Consultancy, congratulations!
Read the full press release here (click).